Details for Patent: 8,062,667
Which drugs does patent 8,062,667 protect, and when does it expire?
Patent 8,062,667 protects QUILLIVANT XR, DYANAVEL XR, KARBINAL ER, ONYDA XR, and TUZISTRA XR, and is included in five NDAs.
This patent has twenty-one patent family members in fourteen countries.
Summary for Patent: 8,062,667
| Title: | Modified release formulations containing drug-ion exchange resin complexes |
| Abstract: | A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described. |
| Inventor(s): | Ketan Mehta, Yu-Hsing Tu |
| Assignee: | Tris Pharma Inc |
| Application Number: | US11/724,966 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,062,667 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; Process; |
Drugs Protected by US Patent 8,062,667
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nextwave | QUILLIVANT XR | methylphenidate hydrochloride | FOR SUSPENSION, EXTENDED RELEASE;ORAL | 202100-001 | Sep 27, 2012 | AB | RX | Yes | Yes | 8,062,667 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Tris Pharma Inc | DYANAVEL XR | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | SUSPENSION, EXTENDED RELEASE;ORAL | 208147-001 | Oct 19, 2015 | RX | Yes | Yes | 8,062,667 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Aytu | KARBINAL ER | carbinoxamine maleate | SUSPENSION, EXTENDED RELEASE;ORAL | 022556-001 | Mar 28, 2013 | RX | Yes | Yes | 8,062,667 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Tris Pharma Inc | ONYDA XR | clonidine hydrochloride | SUSPENSION, EXTENDED RELEASE;ORAL | 217645-001 | May 24, 2024 | RX | Yes | Yes | 8,062,667 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Tris Pharma Inc | TUZISTRA XR | chlorpheniramine polistirex; codeine polistirex | SUSPENSION, EXTENDED RELEASE;ORAL | 207768-001 | Apr 30, 2015 | DISCN | Yes | No | 8,062,667 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,062,667
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E536867 | ⤷ Start Trial | |||
| Australia | 2007227569 | ⤷ Start Trial | |||
| Brazil | PI0709606 | ⤷ Start Trial | |||
| Canada | 2645855 | ⤷ Start Trial | |||
| China | 101400343 | ⤷ Start Trial | |||
| China | 102488652 | ⤷ Start Trial | |||
| Denmark | 2018160 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
